Lung cancer remains a leading cause of cancer related mortality worldwide. Despite
numerous advances in treatments over the past decade, non-small cell lung cancer …

PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …

Background Approximately 20% of patients with non–small-cell lung cancer (NSCLC)
receive a diagnosis of stage III disease. There is no current consensus regarding the most …

The treatment goal for patients with early-stage lung cancer is cure. Multidisciplinary
discussions of surgical resectability and medical operability determine the modality of …

PURPOSE For patients with resectable stage IIIA (N2) non–small-cell lung cancer,
neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1 …

Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …

Lung cancer is the leading cause of cancer mortality worldwide with 1.8 million newly
diagnosed cases, or 13% of all cancers diagnosed, in 2012 [1]. The worldwide numbers are …

Lung cancer continues to be a major global health problem; the disease is diagnosed in
more than 1.6 million new patients each year. However, significant progress is underway in …

Lung cancer is the leading cause of cancer death worldwide. Majority of newly diagnosed
lung cancers are non-small cell lung cancer (NSCLC), of which up to half are considered …

Abstract This Review Article provides a multi-stakeholder view on the current status of
neoadjuvant therapy in lung cancer. Given the success of oncogene-targeted therapy and …